After publication of potentially practice-changing clinical trials, identified through ASCO's signals approach to updating, an updated systematic review was performed for two guideline questions: ...

Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to ...

A recent Scientific Reports study investigated the association between obesity in early pregnancy and long-term post-pregnancy risk of venous thromboembolism (VTE). Study: Prepregnancy overweight and ...

The current system for pregnancy and postnatal blood clot risk assessments is inadequate and could place pregnant women/people at risk of needing follow-on treatment or potentially fatal outcomes, a ...

In honor of World Thrombosis Day (WTD), a disease awareness campaign sponsored by the International Society on Thrombosis and Haemostasis (ISTH), Stago presents a special educational event. The ...

Please provide your email address to receive an email when new articles are posted on . FDA approved rivaroxaban in tablet form and as an oral suspension to treat and reduce the risk for recurrence of ...

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...